Abstract
The first part of the book is concerned with the targeted treatment of cancers with small molecule inhibitors. These are inhibitors that have been designed to counter specific cellular defects that are responsible for initiating and maintaining the disease. The best studied example so far is the treatment of chronic myeloild leukemia (CML) with tyrosine kinase inhibitors, such as imatinib, which has led to impressive treatment responses. Yet, drug-resistant tumor cells present an important barrier to successful treatment, especially in the advanced phase of the disease, and can lead to treatment failure. The dynamics of CML and the evolution of drug-resistant mutants will be investigated in detail in this part of the book, through the lens of mathematical models. The current chapter provides the necessary biological background to the mathematical models.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhang, J., Yang, P., Gray, N.: Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28–39 (2009)
Druker, B.J.: Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1–30 (2004)
Deininger, M.W., Goldman, J.M., Melo, J.V.: The molecular biology of chronic myeloid leukemia. Blood 96(10), 3343–3356 (2000)
An, X., Tiwari, A., Sun, Y., Ding, P., Ashby, C., Chen, Z.: Bcr-abl tyrosine kinase inhibitors in the treatment of philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res. 34(10), 1255–1268 (2010)
Ferdinand, R., Mitchell, S., Batson, S., Tumur, I.: Treatments for chronic myeloid leukemia: a qualitative systematic review. J. Blood Med. 3, 51 (2012)
Deininger, M., Buchdunger, E., Druker, B.: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7), 2640–2653 (2005)
Deininger, M.W., Druker, B.J.: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55(3), 401–423 (2003)
Leitner, A., Hochhaus, A., MĂĽller, M., et al.: Current treatment concepts of cml. Curr. Cancer Drug Targets 11(1), 31 (2011)
Kantarjian, H., Baccarani, M., Jabbour, E., Saglio, G., Cortes, J.: Second-generation tyrosine kinase inhibitors: the future of frontline cml therapy. Clin. Cancer Res. 17(7), 1674–1683 (2011)
Weisberg, E., Manley, P., Cowan-Jacob, S., Hochhaus, A., Griffin, J.: Second generation inhibitors of bcr-abl for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7(5), 345–356 (2007)
Karvela, M., Helgason, G., Holyoake, T.: Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev. Anticancer Ther. 12(3), 381–392 (2012)
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al.: Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci. Signal. 304(5676), 1497 (2004)
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al.: Egf receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U S A 101(36), 13306–13311 (2004)
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Isayama, H., et al.: Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced mapk signals. Cancer Res. 73(7), 2221–2234 (2013)
Adams, J., Kauffman, M.: Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest. 22(2), 304–311 (2004)
Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A.A., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007)
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008)
Melo, J.V., Hughes, T.P., Apperley, J.F.: Chronic myeloid leukemia. Hematology: Am Soc Hematol Educ Book, 2003(1) pp. 132–52 (2003).
Melo, J.V., Barnes, D.J.: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7(6), 441–453 (2007)
Howlader, N., Noone, A., Krapcho, M., Neyman, N., Aminou, R., Altekreuse, S., Kosary, C., Ruhl, J., Tatalovich, Z., Cho, H., et al.: Seer Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda (2012)
Bolin, R., Robinson, W., Sutherland, J., Hamman, R.: Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50(9), 1683–1686 (1982)
Group, C.M.L.T.C.: Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J. Natl. Cancer Inst. 89, 1616–1620 (1997)
Shannon, K.M.: Resistance in the land of molecular cancer therapeutics. Cancer Cell 2(2), 99–102 (2002)
Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., Sawyers, C.L.: Overriding imatinib resistance with a novel abl kinase inhibitor. Science 305(5682), 399–401 (2004)
Tauchi, T., Ohyashiki, K.: Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res. 28(Suppl 1), S39–45 (2004)
Kantarjian, H., Talpaz, M., Giles, F., O’Brien, S., Cortes, J., et al.: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 145(12), 913 (2006)
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J., Arthur, C., et al.: Detection of bcr-abl mutations in patients with cml treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the atp phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 102(1), 276–283 (2003)
Volpe, G., Panuzzo, C., Ulisciani, S., Cilloni, D., et al.: Imatinib resistance in cml. Cancer Lett. 274(1), 1 (2009)
O’Hare, T., Corbin, A., Druker, B.: Targeted cml therapy: controlling drug resistance, seeking cure. Curr. Opin. Genetics Dev. 16(1), 92–99 (2006)
Giles, F., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., Freedman, S.: Mk-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the t315i bcr-abl mutation. Blood 109(2), 500–502 (2007)
Calabretta, B., Perrotti, D.: The biology of cml blast crisis. Blood 103(11), 4010–4022 (2004)
Rodriguez-Brenes, I.A., Komarova, N.L., Wodarz, D.: Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers. Proc. Natl. Acad. Sci. U S A 108(47), 18983–18988 (2011)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Komarova, N.L., Wodarz, D. (2014). An Introduction to Small Molecule Inhibitors and Chronic Myeloid Leukemia. In: Targeted Cancer Treatment in Silico. Modeling and Simulation in Science, Engineering and Technology. Birkhäuser, New York, NY. https://doi.org/10.1007/978-1-4614-8301-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8301-4_2
Published:
Publisher Name: Birkhäuser, New York, NY
Print ISBN: 978-1-4614-8300-7
Online ISBN: 978-1-4614-8301-4
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)